Neuron cell close-up view © GettyImages/koto_feja

FDA committee agrees Biogen’s ALS therapy could have ‘clinical benefit’

A US FDA panel of advisors concluded that there was a lack of substantial evidence to indicate that Biogen’s investigational drug, tofersen, was effective in treating a rare and aggressive form of ALS. But the experts voted unanimously that the investigational product could have a clinical benefit in reducing a protein that is associated with disease severity.

Building an mRNA giant: Moderna’s 7 priorities for 2023

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...

Global Industry News

Hot Topics


Follow us


View more


Featured Suppliers